Ultrasensitive eccDNA Detection for Tumor Diagnostics by Using CRISPR/Cas12a-Coupled Nested PCR
Analytical Chemistry · 02.09.2025 · 97 (34) · 18527-18536
DOI: 10.1021/acs.analchem.5c02316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, online erschienen am 31.07.2025. Verfasst von Gege Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Polymerase Chain Reaction, DNA, Circular, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Ministry of Education of the People's Republic of China, Shanghai Municipal Health Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Extrachromosomal circular DNA (eccDNA) has emerged as a novel biomarker for cancer detection due to its tumor-specific amplification and stable structure in circulation. However, its clinical application is hindered by extremely low abundance in biofluids and the lack of robust detection techniques. To address this, we screened for tumor-associated eccDNA biomarkers and developed NPCC (Nested PCR-CRISPR/Cas12a), a novel method combining nested PCR for ultrasensitive amplification with CRISPR/Cas12a for sequence-specific detection. The assay employs two rounds of junction-specific PCR to enrich eccDNA, followed by CRISPR/Cas12a-mediated cleavage guided by target-specific crRNA. Validation using synthetic circular DNA standards demonstrated a limit of detection (LoD) of 10-6 fM, representing a >100-fold improvement over conventional PCR, with no cross-reactivity to linear or genomic DNA fragments. In plasma samples from 88 cancer patients, NPCC successfully detected multiple tumor-specific eccDNAs, including the hepatocellular carcinoma marker eccDNA-HCC-1 (AUC = 0.8977). NPCC overcomes key technical barriers in liquid biopsy, offering a cost-effective, highly sensitive, and specific platform for noninvasive cancer diagnostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
- Department of Chemistry and Institutes of Biomedical Sciences, Fudan University, Shanghai 200433, China.
- Department of Clinical Laboratory, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201600, China.
ORCID-Profile: Ruixin Sun
Förderung
- Ministry of Education of the People's Republic of China
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Shanghai Municipality
Zitieren
APA
Liu, G., Wu, J., Yang, B., Kong, J., Li, Y., Chen, C., Hu, J., Sun, Z., Hou, Y., Sun, R., & Li, D. (2025). Ultrasensitive eccDNA Detection for Tumor Diagnostics by Using CRISPR/Cas12a-Coupled Nested PCR. Analytical Chemistry, 97(34), 18527-18536. https://doi.org/10.1021/acs.analchem.5c02316
Vancouver
Liu G, Wu J, Yang B, Kong J, Li Y, Chen C, et al. Ultrasensitive eccDNA Detection for Tumor Diagnostics by Using CRISPR/Cas12a-Coupled Nested PCR. Analytical Chemistry. 2025;97(34):18527-18536. doi:10.1021/acs.analchem.5c02316
BibTeX
@article{Liu2025,
author = {Liu, Gege and Wu, Junlu and Yang, Bin and Kong, Jilie and Li, Yaran and Chen, Chen and Hu, Jiayi and Sun, Zujun and Hou, Yanqiang and Sun, Ruixin and Li, Dong},
title = {Ultrasensitive eccDNA Detection for Tumor Diagnostics by Using CRISPR/Cas12a-Coupled Nested PCR},
journal = {Analytical Chemistry},
year = {2025},
volume = {97},
number = {34},
pages = {18527--18536},
doi = {10.1021/acs.analchem.5c02316}
}
EUVIMED